Barinthus Biotherapeutics plc
BRNS
$0.839
$0.0161.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 16.73% | 25.14% | -16.12% | -357.79% | -1,473.03% |
| Total Depreciation and Amortization | 16.64% | 32.27% | 54.66% | 76.92% | 98.49% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 119.30% | -7.37% | -29.71% | 137.78% | 158.27% |
| Change in Net Operating Assets | -57.85% | -261.80% | -99.55% | -104.88% | 211.71% |
| Cash from Operations | 43.17% | -44.45% | -178.83% | -440.30% | -252.89% |
| Capital Expenditure | 83.52% | 92.51% | 95.51% | 57.45% | 11.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 83.52% | 92.51% | 95.29% | 55.14% | 5.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.29% | -40.46% | -57.02% | -67.05% | 320.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 100.00% | 37.00% | -- |
| Cash from Financing | 15.54% | -36.14% | -53.84% | -68.43% | 476.00% |
| Foreign Exchange rate Adjustments | -193.09% | -4.83% | -120.35% | -88.98% | 1,060.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.23% | -36.22% | -186.35% | -562.03% | -165.88% |